Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)
NCT ID: NCT04943575
Last Updated: 2022-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
360 participants
INTERVENTIONAL
2021-06-01
2022-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough
NCT02379637
Point of Care Polymerase Chain Reaction (PCR) Diagnostics of Respiratory Tract Infections in General Practice
NCT06120153
LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases
NCT06837961
Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study
NCT02557958
Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)
NCT00132860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention 1
EZC Pak
EZC Pak
After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
Intervention 2
EZC Pak+D
EZC Pak +D
After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
Placebo
Placebo
After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EZC Pak
After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
EZC Pak +D
After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
Placebo
After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be in good health (don't report any medical conditions asked in the screening questionnaire)
* Seeking OTC remedies to reduce the severity and duration of their common cold symptoms, when they arise
* Must have a thermometer at home
* Must have a blood pressure monitor at home
* Ideally, uses one of the following devices: Apple Watch, Oura Ring, FitBit, other fitness trackers
Exclusion Criteria
* Has any of the following medical conditions:
* ragweed or daisy allergy
* chronic seasonal allergies
* liver disease
* autoimmune or connective tissue disorder (e.g., rheumatoid arthritis, lupus, multiples sclerosis, HIV)
* alcohol consumption more than 7 drinks per week, or more than 3 drinks per occasion
* IV drug use
* renal disease
* females that are pregnant, want to become pregnant for the duration of the study, or who are breastfeeding
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Citruslabs
INDUSTRY
PPC Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne Mitschke, BSc, MSc
Role: PRINCIPAL_INVESTIGATOR
Citruslabs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Citruslabs
Santa Monica, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Radhakrishnan A, Spencer S, Yanamala N, Malepati S. Evaluating the Efficacy and Safety of EZC Pak, a 5-Day Combination Echinacea-Zinc-Vitamin C Dose Pack with or without Vitamin D, in the Management of Outpatient Upper Respiratory Infections. Infect Drug Resist. 2023 May 3;16:2561-2572. doi: 10.2147/IDR.S392087. eCollection 2023.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20214
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.